Member Info for Scully12345

https://www.directors talkinterviews.com/diurnal-group-first-commercial-revenues/412759502 remove the space

https://www.****************************************interviews.com/diurnal-group-first-commercial-revenues/412759502

Results for the year ended 30 June 2018

First commercial revenues recorded for the period from launch in May 2018

SMC Approves The Use of Alkindi

Diurnal believes the use of this product will improve the lives of patients with this rare disease, and their families, by providing access to the first formulation of hydrocortisone specifically designed for paediatric dosing.

So we have these director deals from earlier this year at much higher prices than the current sp:
05-Apr-18 Placing Trade Notifier Information for Diurnal Group Peter Allen 190 GBX 10,000 84722
05-Apr-18 Placing Trade Notifier Information for Diurnal Group Sam Williams 190 GBX 5,500 43274
05-Apr-18 Placing Trade Notifier Information for Diurnal Group John Goddard 190 GBX 5,500 43274

The 12 month low is around 6p right - what's to stop this from revisiting 6p?

Great thanks ArcticFox - are you a holder here?

I'm actually thinking of maybe pulling all of my money out of the markets and maybe shorting the FTSE at this rate lol

Predators what do you think of DNL mate?

Thanks ArcticFox - where did you get the data about the potential 4000 patients please?

I must say i'm in both ALBA and UKOG. More so in ALBa but UKOG has more shares in issue, higher mcap etc. My investment in ALBA feels "safer".

Divi might be cut right?

But I like to pick my own stocks and do my own research? Using a financial planner would take all of the fun out of it for me I think...might as well buy a fund instead?

Chart showing double bottom at 9.5p should bounce. I just put some in DNL today as it was 60% down so no funds for KOOV unfortunately but if it hits my short term 107p sell target tomorrow I'll jump in here.

Looking at today's chart there's a gap to fill between 60p and 107p. This shouldn't take long and we should be back over 100p (which is still cheap) by this Friday. We already tested 55p today and then didn't return anywhere near the day's low so I think the lows have been and gone. Next stop retesting 55p then over 60p to £1+ Easy money to those who are bold imho gla dyor

ArcticFox - no guarantees in anything but now very high probability of approval elsewhere..once approved in one area then others follow easily.

Thank you for your kind words duchess ;) please understand the difference between a paper loss and an actual loss. I'm quite happy having money in here. Yes I do trade a bit (though over days and weeks rarely same day unless I'm lucky) with a perentage of my portfolio but mostly I'm a LTH. I don't really understand the "stitching people up" comment you made? I thought that was your domain? You're the doc right doc?

DNL lost 55% today on very little volume. Bargain of the week as far as I'm concerned. Imho

Only 61.34 million shares in issue lol and tony £28 million mcap reflected in this silly low share price. Tiny free float in sticky hands so it seems. There's no way this share price is staying this low lol imho

Latino sums this up well. A strong buy based on the following: Scots have approved, UK will follow and so will the EU very soon. Excellent news and counteracts the earlier not so good news. With very low free float, this should very bounce high now..gla Rns extract: Given the concentrated prescribing base, and to retain the full value of the product, Diurnal intends to commercialise Alkindi® in the UK and other major European markets. Diurnal has established the commercial infrastructure required to support a successful launch of Alkindi®, focusing its marketing efforts initially on these 0-6 year old patients. As part of the pan-European commercialisation programme for Alkindi®, Diurnal is currently in discussion with various health authorities across Europe to ensure timely launches in other major European countries following the grant of a paediatric use marketing authorisation (PUMA) by the European Commission in February 2018. Alkindi® was launched in Germany in May 2018 and in the UK in September 2018.